MedTrace Logo

TAS-102 and Oxaliplatin for the Treatment of Refractory Stage IV Colon Cancer

NCT04294264 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2024-11-18

No results posted yet for this study

Summary

This phase II trial studies how well TAS-102 and oxaliplatin work in treating patients with stage IV colon cancer. Drugs used in chemotherapy, such as TAS-102 and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Conditions

  • Metastatic Colorectal Carcinoma
  • Recurrent Colon Carcinoma
  • Refractory Colorectal Carcinoma
  • Stage IV Colon Cancer AJCC v7
  • Stage IVA Colon Cancer AJCC v7
  • Stage IVB Colon Cancer AJCC v7

Interventions

DRUG

Oxaliplatin

Given IV

DRUG

Trifluridine and Tipiracil Hydrochloride

Given PO

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Rutgers, The State University of New Jersey

    lead OTHER

Principal Investigators

  • Howard S Hochster · Rutgers Cancer Institute of New Jersey

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-12
Primary Completion
2024-03-27
Completion
2026-03-27
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04294264 on ClinicalTrials.gov